.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Diabetic cardiomyopathy remains a significant clinical challenge for healthcare providers managing type 2 diabetes mellitus (T2DM). Recent experimental evidence suggests that the neurokinin-1 receptor (NK-1R) plays a pivotal role in protecting the heart from structural damage. This discovery offers a novel pathway for diabetic cardiomyopathy treatment, specifically targeting the adverse remodeling caused by chronic hyperglycemia.
In this study, researchers investigated the effects of NK-1R activation in diabetic mouse models. They administered GR73632, a specific NK-1R agonist, to male Lepr mice for four weeks. Consequently, the treated mice exhibited a significant reduction in cardiac fibrosis. Furthermore, the activation of this receptor led to improved diastolic function, which is often the first sign of cardiac impairment in diabetic patients.
Moreover, the study highlighted the anti-inflammatory properties of NK-1R signaling. Activation of the receptor promoted an anti-inflammatory macrophage phenotype and reduced mast cell infiltration. Additionally, it significantly decreased the production of collagen I in high-glucose conditions. Notably, the treatment suppressed the NF-κB signaling pathway by reducing P65 phosphorylation and CCL2 chemokine release.
The findings confirm that NK-1R is the primary anti-fibrotic receptor for substance P in the heart. This mechanism likely involves direct effects on both cardiac fibroblasts and macrophages. Therefore, targeting this pathway could help prevent the progression of heart failure in diabetic individuals. These results provide a robust foundation for future clinical trials focusing on neurogenic inflammation and cardiac repair.
NK-1R activation reduces the production of collagen I and suppresses inflammatory pathways like NF-κB, which helps prevent cardiac stiffness and fibrosis.
Substance P levels often drop in diabetes. Replacing its action through NK-1R agonists helps restore anti-inflammatory and anti-fibrotic signaling in the myocardium.
Yes, experimental data shows that activating this receptor improves diastolic function, allowing the heart to fill more effectively during the relaxation phase.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Widiapradja A et al. Neurokinin-1 receptor activation protects against cardiac fibrosis, inflammation and diastolic dysfunction in type 2 diabetic mice. Br J Pharmacol. 2026 Apr 25. doi: 10.1111/bph.70440. PMID: 42033177.
Mouton AJ, et al. Inflammation and fibrosis in the diabetic heart. Circulation Research. 2020;126(11):1611-1614.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new study reveals that activating the neurokinin-1 receptor (NK-1R) can significantly reduce cardiac fibrosis and improve heart function in diabetic model...
4 months ago
A clinical comparison of extravascular and subcutaneous implantable cardioverter-defibrillators, detailing patient selection, pacing capabilities, and implantation nuances.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
